CORRECTION

Correction: Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma

Arghya Ray, Yan Song, Ting Du, Dharminder Chauhan and Kenneth C. Anderson

© The Author(s), under exclusive licence to Springer Nature Limited 2021

Oncogene (2021) 40:6057; <https://doi.org/10.1038/s41388-021-01996-y>

Correction to: *Oncogene*

<https://doi.org/10.1038/s41388-020-1172-0>

published online 05 February 2020

Unfortunately, the conflict of interest disclosures are incomplete.

The complete conflict of interest is given below.

CONFLICT OF INTEREST

KCA is on Advisory board of Celgene, Millenium-Takeda, Gilead, Janssen, and Bristol Myers Squibb, and is a Scientific Founder with financial interest in Acetylon, Oncopep and C4 Therapeutics. DC is consultant to Stemline Therapeutic, Inc., Oncopeptides Ab; and Equity owner in C4 Therapeutics. The remaining authors declare no conflict of interest.

The original article has been corrected.